{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T02:46:50Z","timestamp":1791082010659,"version":"4.1.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,2,8]],"date-time":"2020-02-08T00:00:00Z","timestamp":1581120000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2020,2,8]],"date-time":"2020-02-08T00:00:00Z","timestamp":1581120000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"MSD China Holding Co., Ltd."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1007\/s10637-020-00903-8","type":"journal-article","created":{"date-parts":[[2020,2,8]],"date-time":"2020-02-08T14:02:16Z","timestamp":1581170536000},"page":"507-514","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Mirtazapine, a dopamine receptor inhibitor, as a secondary prophylactic for delayed nausea and vomiting following highly emetogenic chemotherapy: an open label, randomized, multicenter phase III trial"],"prefix":"10.1007","volume":"38","author":[{"given":"Jun","family":"Cao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quchang","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shusen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Ragaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuee","family":"Teng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biyun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhonghua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leiping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhimin","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xichun","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,8]]},"reference":[{"key":"903_CR1","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1634\/theoncologist.4-3-191","volume":"4","author":"PJ Hesketh","year":"1999","unstructured":"Hesketh PJ (1999) Defining the emetogenicity of cancer chemotherapy regimens: relevance to clinical practice. Oncologist. 4:191\u2013196","journal-title":"Oncologist."},{"key":"903_CR2","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.critrevonc.2015.12.001","volume":"99","author":"S Sommariva","year":"2016","unstructured":"Sommariva S, Pongiglione B, Tarricone R (2016) Impact of chemotherapy-induced nausea and vomiting on health-related quality of life and resource utilization: a systematic review. Crit Rev Oncol Hematol 99:13\u201336","journal-title":"Crit Rev Oncol Hematol"},{"issue":"4","key":"903_CR3","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1200\/JCO.2015.64.3635","volume":"34","author":"PJ Hesketh","year":"2016","unstructured":"Hesketh PJ, Bohlke K, Lyman GH et al (2016) Antiemetics: American Society of Clinical Oncology focused guideline update. Am Soc Clin Oncol J Clin Oncol 34(4):381\u2013386","journal-title":"Am Soc Clin Oncol J Clin Oncol"},{"issue":"suppl 5","key":"903_CR4","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1093\/annonc\/mdq194","volume":"21","author":"F Roila","year":"2010","unstructured":"Roila F, Herrstedt J, Aapro M et al (2010) ESMO\/MASCC guidelines. Working group. Guideline update for MASCC and ESMO in the prevention of chemotherapy and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 21(suppl 5):232\u2013243","journal-title":"Ann Oncol"},{"key":"903_CR5","unstructured":"NCCN National Comprehensive Cancer Network. Antiemesis: Clinical Practice Guidelines in Oncology, v 2. 2017. Available at: www.nccn.org. 2017"},{"issue":"11","key":"903_CR6","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1111\/j.1349-7006.2010.01689.x","volume":"101","author":"T Takahashi","year":"2010","unstructured":"Takahashi T, Hoshi E, Takagi M et al (2010) Multicenter, phase II, placebo-controlled, double-blind, randomized study of Aprepitant in Japanese patients receiving high-dose cisplatin. Cancer Sci 101(11):2455\u20132461","journal-title":"Cancer Sci"},{"key":"903_CR7","doi-asserted-by":"publisher","first-page":"4112","DOI":"10.1200\/JCO.2003.01.095","volume":"21","author":"PJ Hesketh","year":"2003","unstructured":"Hesketh PJ, Grunberg SM, Gralla RJ et al (2003) The oral neurokinin-1 antagonist Aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin \u2013 the Aprepitant protocol 052 study group. J Clin Oncol 21:4112\u20134119","journal-title":"J Clin Oncol"},{"key":"903_CR8","doi-asserted-by":"publisher","first-page":"3090","DOI":"10.1002\/cncr.11433","volume":"97","author":"S Poli-Bigelli","year":"2003","unstructured":"Poli-Bigelli S, Rodrigues-Pereira J, Carides AD et al (2003) Aprepitant protocol 054 study group. Addition of the neurokinin 1 receptor antagonist Aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 97:3090\u20133098","journal-title":"Cancer"},{"key":"903_CR9","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1093\/annonc\/mdl019","volume":"17","author":"HJ Schmoll","year":"2006","unstructured":"Schmoll HJ, Aapro MS, Poli-Bigelli S et al (2006) Comparison of an Aprepitant regimen with a multiple-day Ondansetron regimen, both with dexamethasone, for antiemetic efficacy inhigh-dose cisplatin treatment. Ann Oncol 17:1000\u20131006","journal-title":"Ann Oncol"},{"issue":"2","key":"903_CR10","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/0893-133X(94)00129-N","volume":"14","author":"FP Bymaster","year":"1996","unstructured":"Bymaster FP, Calligaro DO, Falcone JF et al (1996) Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology. 14(2):87\u201396","journal-title":"Neuropsychopharmacology."},{"issue":"1","key":"903_CR11","first-page":"24","volume":"5","author":"MV Brafford","year":"2014","unstructured":"Brafford MV, Glode A (2014) Olanzapine: an antiemetic option for chemotherapy-induced nausea and vomiting. J Adv Pract Oncol 5(1):24\u201329","journal-title":"J Adv Pract Oncol"},{"issue":"14","key":"903_CR12","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1056\/NEJMra1515442","volume":"374","author":"RM Navari","year":"2016","unstructured":"Navari RM, Aapro M (2016) Antiemetic prophylaxis for chemotherapy- induced nausea and vomiting. N Engl J Med 374(14):1356\u20131367","journal-title":"N Engl J Med"},{"issue":"1","key":"903_CR13","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s00520-016-3386-9","volume":"25","author":"S Mukhopadhyay","year":"2017","unstructured":"Mukhopadhyay S, Kwatra G, Alice KP et al (2017) Role of olanzapine in chemotherapy-induced nausea and vomiting on platinum-based chemotherapy patients: a randomized controlled study. Support Care Cancer 25(1):145\u2013154","journal-title":"Support Care Cancer"},{"issue":"2","key":"903_CR14","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s12013-014-0489-0","volume":"72","author":"X Wang","year":"2015","unstructured":"Wang X, Wang L, Wang H et al (2015) Effectiveness of olanzapine combined with Ondansetron in prevention of chemotherapy-induced nausea and vomiting of non-small cell lung cancer. Cell Biochem Biophys 72(2):471\u2013473","journal-title":"Cell Biochem Biophys"},{"key":"903_CR15","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/1756-9966-28-131","volume":"28","author":"L Tan","year":"2009","unstructured":"Tan L, Liu J, Liu X et al (2009) Clinical research of olanzapine for prevention of chemotherapy-induced nausea and vomiting. J Exp Clin Cancer Res 28:131","journal-title":"J Exp Clin Cancer Res"},{"issue":"4","key":"903_CR16","doi-asserted-by":"publisher","first-page":"141","DOI":"10.12788\/jcso.0245","volume":"14","author":"R Navari","year":"2016","unstructured":"Navari R, Nagy C, Le-Rademacher J et al (2016) Olanzapine versus fosAprepitant for the prevention of concurrent chemotherapy radiotherapy-induced nausea and vomiting. J Community Support Oncol 14(4):141\u2013147","journal-title":"J Community Support Oncol"},{"issue":"3","key":"903_CR17","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s40265-013-0019-1","volume":"73","author":"RM Navari","year":"2013","unstructured":"Navari RM (2013) Management of chemotherapy-induced nausea and vomiting: focus on newer agents and new uses for older agents. Drugs. 73(3):249\u2013262","journal-title":"Drugs."},{"issue":"Suppl 4","key":"903_CR18","first-page":"19","volume":"57","author":"T de Boer","year":"1996","unstructured":"de Boer T (1996) The pharmacologic profile of mirtazapine. J Clin Psychiatry 57(Suppl 4):19\u201325","journal-title":"J Clin Psychiatry"},{"key":"903_CR19","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/j.1600-0447.1997.tb05956.x","volume":"391","author":"D Nutt","year":"1997","unstructured":"Nutt D (1997) Mirtazapine: pharmacology in relation to adverse effects. Acta Psychiatr Scand Suppl 391:31\u201337","journal-title":"Acta Psychiatr Scand Suppl"},{"issue":"4","key":"903_CR20","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1111\/j.1365-2354.2006.00760.x","volume":"16","author":"RE Kast","year":"2007","unstructured":"Kast RE, Foley KF (2007) Cancer chemotherapy and cachexia: mirtazapine and olanzapine are 5-HT3 antagonists with good antiemesis effects. Eur J Cancer Care (Engl) 16(4):351\u2013354","journal-title":"Eur J Cancer Care (Engl)"},{"key":"903_CR21","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s00404-003-0502-0","volume":"268","author":"A Rohde","year":"2003","unstructured":"Rohde A, Dembinski J, Dorn C (2003) Mirtazapine (Remergil) for treatment resistant hyperemesis gravidarum: rescue of a twin pregnancy. Arch Gynecol Obstet 268:219\u2013221","journal-title":"Arch Gynecol Obstet"},{"key":"903_CR22","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1381\/0960892053923923","volume":"15","author":"FV Teixeira","year":"2005","unstructured":"Teixeira FV, Novaretti TM, Pilon B et al (2005) Mirtazapine (Remeron) as treatment for non-mechanical vomiting after gastric bypass. Obes Surg 15:707\u2013709","journal-title":"Obes Surg"},{"key":"903_CR23","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/S0885-3924(02)00381-0","volume":"23","author":"DE Theobald","year":"2002","unstructured":"Theobald DE, Kirsh KL, Holtsclaw E et al (2002) An open-label, crossover trial of mirtazapine (15 and 30 mg) in cancer patients with pain and other distressing symptoms. J Pain Symptom Manag 23:442\u2013447","journal-title":"J Pain Symptom Manag"},{"key":"903_CR24","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1176\/appi.psy.41.4.356","volume":"41","author":"DS Thompson","year":"2000","unstructured":"Thompson DS (2000) Mirtazapine for the treatment of depression and nausea in breast and gynecological oncology. Psychosomatics. 41:356\u2013369","journal-title":"Psychosomatics."},{"key":"903_CR25","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0, published on May 28, 2009"},{"issue":"5","key":"903_CR26","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/BF00434947","volume":"1","author":"CM Lindley","year":"1992","unstructured":"Lindley CM, Hirsch JD, O'Neill CV et al (1992) Quality of life consequences of chemotherapy-induced emesis. Qual Life Res 1(5):331\u2013340","journal-title":"Qual Life Res"},{"issue":"6","key":"903_CR27","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1007\/s00280-014-2446-4","volume":"73","author":"W Hu","year":"2014","unstructured":"Hu W, Fang J, Nie J et al (2014) Addition of Aprepitant improves protection against cisplatin-induced emesis when a conventional anti-emetic regimen fails. Cancer Chemother Pharmacol 73(6):1129\u20131136","journal-title":"Cancer Chemother Pharmacol"},{"issue":"7","key":"903_CR28","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1038\/sj.bjc.6603048","volume":"94","author":"J Vardy","year":"2006","unstructured":"Vardy J, Chiew KS, Galica J et al (2006) Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy. Br J Cancer 94(7):1011\u20131015","journal-title":"Br J Cancer"},{"issue":"1","key":"903_CR29","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s00520-014-2372-3","volume":"23","author":"S Yu","year":"2015","unstructured":"Yu S, Burke TA, Chan A et al (2015) Antiemetic therapy in Asia Pacific countries for patients receiving moderately and highly emetogenic chemotherapy--a descriptive analysis of practice patterns, antiemetic quality of care, and use of antiemetic guidelines. Support Care Cancer 23(1):273\u2013382","journal-title":"Support Care Cancer"},{"issue":"6","key":"903_CR30","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1634\/theoncologist.2014-0438","volume":"20","author":"TL Ng","year":"2015","unstructured":"Ng TL, Hutton B, Clemons M (2015) Chemotherapy-induced nausea and vomiting: time for more emphasis on nausea? Oncologist. 20(6):576\u2013583","journal-title":"Oncologist."},{"key":"903_CR31","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1056\/NEJMoa1515725","volume":"375","author":"RM Navari","year":"2016","unstructured":"Navari RM, Qin R, Ruddy KJ et al (2016) Olanzapine for the prevention of chemotherapy-induced nausea and vomiting. N Engl J Med 375:134\u2013142","journal-title":"N Engl J Med"},{"issue":"1","key":"903_CR32","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1111\/j.1440-1819.2007.01778.x","volume":"62","author":"SW Kim","year":"2008","unstructured":"Kim SW, Shin IS, Kim JM et al (2008) Effectiveness of mirtazapine for nausea and insomnia in cancer patients with depression. Psychiatry Clin Neurosci 62(1):75\u201383","journal-title":"Psychiatry Clin Neurosci"},{"issue":"30","key":"903_CR33","doi-asserted-by":"publisher","first-page":"3413","DOI":"10.1200\/JCO.2013.55.0095","volume":"32","author":"T Schmitt","year":"2014","unstructured":"Schmitt T, Goldschmidt H, Neben K et al (2014) Aprepitant, granisetron, and dexamethasone for prevention of chemotherapy-induced nausea and vomiting after high-dose melphalan in autologous transplantation for multiple myeloma: results of a randomized, placebo-controlled phase III trial. J Clin Oncol 32(30):3413\u20133420","journal-title":"J Clin Oncol"},{"key":"903_CR34","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s00520-016-3388-7","volume":"25","author":"M Chasen","year":"2017","unstructured":"Chasen M, Urban L, Schnadig I et al (2017) Rolapitant improves quality of life of patients receiving highly or moderately emetogenic chemotherapy. Support Care Cancer 25:85\u201392","journal-title":"Support Care Cancer"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-020-00903-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-020-00903-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-020-00903-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T13:44:59Z","timestamp":1678542299000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-020-00903-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,8]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["903"],"URL":"https:\/\/doi.org\/10.1007\/s10637-020-00903-8","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,8]]},"assertion":[{"value":"8 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All authors declare they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The Fudan University Shanghai Cancer Center Ethic Committee for Clinical Investigation approved the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all study participants.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}